VIA
TVTX icon

Virtus Investment Advisers’s Travere Therapeutics TVTX Stock Holding History

Virtus Investment Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$720K Buy
24,239
+4,619
+24% +$138K 0.2% 175
2025
Q4 		$750K Sell
19,620
-10,125
-34% -$329K 0.2% 151
2025
Q3 		$711K Hold
29,745
– – 0.2% 168
2025
Q2 		$440K Buy
29,745
+9,699
+48% +$161K 0.15% 205
2025
Q1 		$359K Buy
+20,046
New +$407K 0.1% 223

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtus Investment Advisers's TVTX Position: Q1 2026 in Review

Virtus Investment Advisers increased its Travere Therapeutics (TVTX) stake by 24% in Q1 2026, buying an estimated $138K and bringing the position to 24,239 shares worth $720K. The position accounts for 0.2% of the portfolio, ranked #175.

Virtus Investment Advisers first reported a position in TVTX in Q1 2025 and has held it in 5 quarters since. The position peaked at $750K in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • Virtus Investment Advisers held 24,239 shares of Travere Therapeutics worth $720K as of Q1 2026.
  • Virtus Investment Advisers bought 4,619 Travere Therapeutics shares in Q1 2026, an estimated $138K.
  • Travere Therapeutics made up 0.2% of Virtus Investment Advisers's portfolio in Q1 2026, its #175 holding.
  • Virtus Investment Advisers first reported a position in Travere Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Virtus Investment Advisers's Travere Therapeutics position peaked at $750K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.